DOI: 10.1055/s-00035024

Thrombosis and Haemostasis

Ausgabe 01 · Volume 41 · 1979 DOI: 10.1055/s-009-45108

Dedication

  • 3
    SHERRY, Sol:

    A Tribute to Kenneth M. Brinkhous, M. D.

  • 27
    Morris, G.K.:

    Preoperative Prediction of Postoperative Deep Vein Thrombosis

  • 33
    Browse, N. L.:

    Comments by the Designated Discussant

  • 37

    General Discussion

  • 43
    Gent, M.; Hirsh, J.:

    Definition of High Risk/High Response Population for Stroke in Patients with Transient Ischemic Attacks

  • 59

    General Discussion

  • 63
    Prentice, C. R. M.:

    Which Patients with Coronary Artery Disease are Most Prone to Develop a Coronary Artery Event (Presumably Thrombosis)?

  • 73
    Oliver, M. F.:

    Design of Clinical Trials in Thrombosis

  • 77

    General Discussion

  • 83
    Tudor Davies, W.:

    South Wales Multicenter Trial of Prophylactic Dextran 70 after Surgery: a Clinically Oriented Randomized Double-blind Trial

  • 91
    Vessey, M. P.:

    Comments of an Epidemiologist

  • 95
    Salzman, Edwin W.:

    The Surgeon’s Comments I

  • 97
    Kakkar, V. V.:

    The Surgeon’s Comments 11

  • 99
    Saldeen, Tom:

    Invited Discussant

  • 105
    Kakkar, V. V.:

    The Logistic Problems Encountered in the Multicenter Trial of Low-Dose Heparin Prophylaxis

  • 121
    Browse, N. L.:

    The Prophylaxis of Deep Vein Thrombosis

  • 123
    Gent, M.; Sackett, D. L.:

    The Qualification and Disqualification of Patients and Events in Long-Term Cardiovascular Clinical Trials

  • 135
    Fields, W.S.; Lemak, N.A.; Frankowski, R.F.; Hardy, R.J.:

    Controlled Trial of Aspirin in Cerebral Ischemia (AITIA Study)

  • 143
    Armitage, P.:

    The Statistician’s Comments

  • 147
    Ross Russell, R. W.:

    The Neurologist’s Comments

  • 151
    Whisnant, Jack P.:

    Invited Discussant

  • 153

    General Discussion

  • 163
    Gent, M.:

    The Canadian Cooperative Study of Platelet Suppressant Therapy in Threatened Stroke

  • 171
    Armitage, P.:

    The Statistician’s Comments

  • 177
    Ross Russell, R.W.:

    The Neurologist’s Comments

  • 181
    Whisnant, J.P.:

    Invited Discussant

  • 187

    General Discussion

  • 197
    Sherry, Sol:

    The Anturane Reinfarction Trial

  • 203
    Meade, T. W.:

    The Epidemiologist’s Comments

  • 209
    Oliver, M.F.:

    The Cardiologist’s Comments

  • 213
    Klimt, C.R.:

    Invited Discussant

  • 217
    Boissel, J. P.:

    Invited discussant

  • 221

    General Discussion

  • 225
    Breddin, K.; Loew, D.; Lechner, K.; Überla, K.; Walter, E.:

    Secondary Prevention of Myocardial Infarction Comparison of Acetylsalicylic Acid, Phenprocoumon and Placebo

  • 237
    Überla, K.:

    Statistical Evidence of the German-Austrian Secondary Prevention Trial

  • 243
    Meade, T.W.:

    The Epidemiologist’s Comments

  • 247
    Oliver, M.F.:

    The Cardiologist’s Comments

  • 249
    Loeliger, E. A.:

    Invited Discussant of the German-Austrian Study Group Report

  • 255
    Barrillon, A.; Kusmierek, J.; Gerbaux, A.:

    Occlusive Coronary Thrombosis and Oral Anticoagulants

  • 265

    General Discussion of the German-Austrian Study Group Report

  • 267
    Brinkhous, K.M.:

    Armand J. Quick, Ph.D., M.D. 1894-1978

  • 271
    Brinkhous, K.M.:

    Benjamin Alexander, M.D. 1909-1978